The effects of Dexmedetomidine on Recovery from Acute KIdney INjury (DRAIN): a single-center retrospective review using the Medical Information Mart for Intensive Care, fourth edition (MIMIC-IV)

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective review shows dexmedetomidine is linked to slower recovery from acute kidney injury in adults, suggesting complex implications.

Dexmedetomidine is associated with a statistically significant 53.7% increase in the risk of recovery from AKI.
Patients receiving dexmedetomidine experience an average hospital length of stay increase of 18.98% and ICU stay by 32.56%.
Sensitivity analysis showed an adjusted hazard ratio of 1.42 for time to AKI recovery in dexmedetomidine patients.
Research indicates lower odds of in-hospital mortality for patients receiving dexmedetomidine, averaging 0.6 times compared to those who do not.

Jones et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective review shows dexmedetomidine is linked to slower recovery from acute kidney injury in adults, suggesting complex implications.